Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion
Open Access
- 28 October 2022
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (1) , 36.e1-36.e5
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplantBone Marrow Transplantation, 2020
- Treatment-related mortality following autologous hematopoietic stem cell transplantation is unaffected by timing of G-CSF administrationBone Marrow Transplantation, 2020
- Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2015
- Autologous Transplantation and Maintenance Therapy in Multiple MyelomaNew England Journal of Medicine, 2014
- Fifty Years of Melphalan Use in Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2013
- Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high‐dose melphalan in patients with multiple myelomaEuropean Journal of Haematology, 2012
- Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2012
- Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trialBlood, 2002
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- High-dose intravenous melphalan: a review.Journal of Clinical Oncology, 1995